State Street Corp grew its position in Allakos Inc (NASDAQ:ALLK) by 141.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 767,711 shares of the company’s stock after purchasing an additional 449,407 shares during the quarter. State Street Corp owned about 1.58% of Allakos worth $60,365,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC acquired a new position in shares of Allakos in the third quarter valued at approximately $42,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Allakos during the third quarter worth approximately $113,000. Bank of Montreal Can acquired a new stake in Allakos during the second quarter worth approximately $63,000. Amundi Pioneer Asset Management Inc. acquired a new stake in Allakos during the first quarter worth approximately $142,000. Finally, SG Americas Securities LLC grew its position in Allakos by 27.5% during the second quarter. SG Americas Securities LLC now owns 4,819 shares of the company’s stock worth $209,000 after buying an additional 1,040 shares in the last quarter. 68.68% of the stock is currently owned by institutional investors.
A number of brokerages recently issued reports on ALLK. ValuEngine downgraded Allakos from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research downgraded Allakos from a “buy” rating to a “hold” rating in a research report on Friday, August 16th.
Shares of NASDAQ:ALLK opened at $125.97 on Friday. The company has a market capitalization of $5.89 billion, a P/E ratio of -57.26 and a beta of -1.11. Allakos Inc has a 1 year low of $30.32 and a 1 year high of $139.99. The business’s 50 day simple moving average is $87.06 and its 200 day simple moving average is $67.50.
Allakos (NASDAQ:ALLK) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.04). Sell-side analysts predict that Allakos Inc will post -1.88 EPS for the current fiscal year.
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Read More: 52-Week Highs and Lows
Want to see what other hedge funds are holding ALLK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allakos Inc (NASDAQ:ALLK).
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.